Abstract
BackgroundTo investigate the importance of adjuvant chemotherapy in locally advanced rectal cancer (≥ cT3 or N+) staged ypT0–2 ypN0 on final histological work-up after neoadjuvant chemoradiation and radical resection.MethodsThe clinical course of patients with rectal cancer and ypT0–2 ypN0 stages after neoadjuvant chemoradiation and radical resection was analyzed from 1999 to 2012. Patients were divided into two groups depending on whether adjuvant chemotherapy was administered or not. Overall survival, distant metastases, and local recurrence were compared between both groups.ResultsFifty-four patients with adjuvant (ACT) and 50 patients without adjuvant chemotherapy (NACT) after neoadjuvant chemoradiation followed by radical resection for rectal cancer were included in the analysis. Mean follow-up was 68 ± 33.7 months. One patient without adjuvant chemotherapy and none in the ACT group developed a local recurrence. Five patients in the NACT group and three patients in the ACT group had distant recurrences. Median disease-free survival for all patients was 65.5 ± 34.5 months. Multivariate analysis showed adjuvant chemotherapy to be the most relevant factor for disease-free and overall survival. Patients staged ypT2 ypN0 showed a significantly better disease-free survival after application of adjuvant chemotherapy. Disease-free survival in ypT0–1 ypN0 patients showed no correlation to the administration of adjuvant chemotherapy.ConclusionAdministration of adjuvant chemotherapy after neoadjuvant chemoradiation and radical resection in rectal cancer improved disease-free and overall survival of patients with ypT0–2 ypN0 tumor stages in our study. In particular, ypT2 ypN0 patients seem to profit from adjuvant treatment.
Highlights
To investigate the importance of adjuvant chemotherapy in locally advanced rectal cancer (≥ cT3 or N+) staged ypT0–2 ypN0 on final histological work-up after neoadjuvant chemoradiation and radical resection
Current guidelines for the treatment of colorectal cancer in Germany recommend the administration of adjuvant chemotherapy for all rectal cancer patients after neoadjuvant chemoradiation and total mesorectal excision (TME)
We investigated patients with locally advanced rectal cancer in clinical staging (UICC stages II and III) treated with neoadjuvant chemoradiation and TME and staged ypT0–2 ypN0
Summary
To investigate the importance of adjuvant chemotherapy in locally advanced rectal cancer (≥ cT3 or N+) staged ypT0–2 ypN0 on final histological work-up after neoadjuvant chemoradiation and radical resection. Neoadjuvant chemoradiation is a considered standard treatment for locally advanced rectal cancer [1]. Current guidelines for the treatment of colorectal cancer in Germany recommend the administration of adjuvant chemotherapy for all rectal cancer patients after neoadjuvant chemoradiation and total mesorectal excision (TME), Galata et al World Journal of Surgical Oncology (2018) 16:156. In adherence to the German national guidelines from before 2008, ypT0–2 ypN0 patients were not treated with postoperative chemotherapy (NACT) at our institution. We investigated patients with locally advanced rectal cancer in clinical staging (UICC stages II and III) treated with neoadjuvant chemoradiation and TME and staged ypT0–2 ypN0. On the basis of a prospectively maintained database, the oncologic outcomes of these patients were analyzed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
